Please login to the form below

Not currently logged in
Email:
Password:

company restructuring

This page shows the latest company restructuring news and features for those working in and with pharma, biotech and healthcare.

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

It is part of a restructuring drive at the big pharma company that aims to slim down its operations, concentrate resources on its more-profitable branded medicines division, and provide it ... There are no changes to the terms of the deal, which will see

Latest news

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    Faces a challenging period as big brands experience a slowdown. Pfizer’s restructuring into a leaner company is still ongoing, and in the meantime its facing a challenging period as big ... Pfizer’s new chief executive Albert Bourla said on a

  • Antibiotic biotech Melinta files for bankruptcy Antibiotic biotech Melinta files for bankruptcy

    Melinta had been raising its financial concerns for much of 2019, ultimately culminating in this bankruptcy plan which will see the New-Jersey, US-based company undergo a major restructuring agreement. ... As a result, Melinta will lay off approximately

  • Sanofi sheds jobs in R&D restructuring Sanofi sheds jobs in R&D restructuring

    466 jobs will be cut, with diabetes and cardiovascular R&D bearing the brunt of the restructuring at the French pharma company. ... Sanofi’s restructuring of its R&D organisation is headed by John Reed, its new R&D chief, who joined from Roche last year

  • Boehringer starts to feel impact of Spiriva generics Boehringer starts to feel impact of Spiriva generics

    To that end, Boehringer is in the throes of a major restructuring of its businesses. ... Boehringer has also embarked on a restructuring of its human pharmaceuticals and innovation corporate board divisions, eliminating around 725 jobs in the US.

  • Astellas sells dermatology unit to Leo for €675m Astellas sells dermatology unit to Leo for €675m

    Continuesthe company's restructuring drive. Japan's Astellas has continued the restructuring of its business started in 2013 with the sale of its dermatology operations to Danish firm Leo Pharma. . ... There have been rumours of a sale of the unit since

More from news
Approximately 1 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    the company has amassed more than 500, 000 patient years’ experience over the product’s six years. ... It accelerated when President and CEO Christophe Weber took the helm in 2015, as the first non-Japanese leader of the 239-year- old company, and he

  • Pharma deals during September 2014 Pharma deals during September 2014

    Company restructuring and portfolio rationalisation. Following restructuring by Pfizer, GSK, Novartis, Lilly and Merck &Co, Bayer has jumped on the portfolio rationalisation bandwagon with its decision to spin off as a ... separate listed company its

  • Sandra Rafferty: 'If I could change one thing…' Sandra Rafferty: 'If I could change one thing…'

    I met a friend recently who has been a sales rep for a number of years and she told me her company had been through a restructuring process to adopt the ... It is only when the perception of KAM is changed and a KAM approach is adopted fully across the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Sue Mahony to retire as president of Lilly Oncology Sue Mahony to retire as president of Lilly Oncology

    She also most recently led the refocusing of the company’s oncology R&D strategy. ... Prior to this, as senior vice president of human resources and diversity, Mahony played in a role in restructuring the company into business units.

  • AZ names Dunoyer as CFO AZ names Dunoyer as CFO

    He succeeds Simon Lowth as company restructure continues apace. AstraZeneca (AZ) has announced that Marc Dunoyer will take over from Simon Lowth as the company's chief financial officer. ... Group. Dunoyer only joined AZ in June this year as executive VP,

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics